These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 33535978)

  • 1. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
    Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
    BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
    J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Integrated Prediction of Clinical and Pathological Factors on the Prognosis of Intrahepatic Cholangiocarcinoma.
    Chen G; Li S; Xia A; Xing Y; Liang W
    Am Surg; 2024 Jun; 90(6):1481-1490. PubMed ID: 38549438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
    Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
    Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures.
    Bernatz S; Schulze F; Bein J; Bankov K; Mahmoudi S; Grünewald LD; Koch V; Stehle A; Schnitzbauer AA; Walter D; Finkelmeier F; Zeuzem S; Vogl TJ; Wild PJ; Kinzler MN
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):357. PubMed ID: 39034327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection.
    Huang J; Wang X; Zhu Y; Wang Z; Li J; Xu D; Wang S; Li TE; Lu L
    J Surg Oncol; 2019 Jan; 119(1):40-46. PubMed ID: 30480811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
    Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
    Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
    Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.